Retrospective Study
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 28, 2017; 23(40): 7265-7273
Published online Oct 28, 2017. doi: 10.3748/wjg.v23.i40.7265
Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients
Daniel Lew, Soon Man Yoon, Xiaofei Yan, Lori Robbins, Talin Haritunians, Zhenqiu Liu, Dalin Li, Dermot PB McGovern
Daniel Lew, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States
Soon Man Yoon, Xiaofei Yan, Talin Haritunians, Zhenqiu Liu, Dalin Li, Dermot PB McGovern, F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States
Lori Robbins, Department of Gastroenterology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States
Author contributions: Lew D collected and analyzed the data, and drafted the manuscript; Yoon SM and Robbins L helped collect the data and edit the manuscript; Yan X and Li D helped with the technical and statistical analysis; Liu Z and Haritunians T helped analyze the data and edit the manuscript; McGovern DPB designed and supervised the study, and revised the manuscript for important intellectual content; all authors have read and approved the final version to be published.
Institutional review board statement: The study was reviewed and approved by the Cedars-Sinai Institutional Review Board (IRB #3358).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: DPBM reports consulting for Janssen, UCB, Pfizer, Celgene, and Merck.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dermot PB McGovern, MD, PhD, F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States. dermot.mcgovern@cshs.org
Telephone: +1-310-4234100
Received: August 5, 2017
Peer-review started: August 5, 2017
First decision: August 14, 2017
Revised: August 25, 2017
Accepted: September 13, 2017
Article in press: September 13, 2017
Published online: October 28, 2017
Core Tip

Core tip: Tumor necrosis factor-α (TNF-α) plays a key role in the development and progression of inflammatory bowel disease (IBD). Anti-TNF therapy is highly efficacious in treating IBD patients, but many experience adverse events. Few studies have evaluated factors associated with adverse events to anti-TNF therapy. In this study, we found some genetic associations and pathways that are enriched for genes associated with the development of adverse events. Future studies will need to confirm these findings as the ability to identify subjects at high risk may help clinicians anticipate and therefore prevent or avoid these adverse events in the future.